Whereas this highly generalizable benefit speaks to the likely utility of MAP4K4 inhibitors beyond merely DOX-induced cardiotoxicity, such results also point to a reciprocal concern, that MAP4K4 inhibitors, if capable of acting as a broad survival signal, might interfere with tumour cell killing, notwithstanding current interest in the cancer field regarding the participation of MAP4K4 in tumor angiogenesis, tumor cell motility, and metastasis54–59. The gene discussed is MAP4K4; the disease is cancer.